Precision hails phase 1/2 data as proof it could deliver the first approved off-the-shelf CAR-T

Gene editing biotech Precision BioSciences is touting phase 1/2 results as proof it could bring the first off-the-shelf CAR-T drug to market.

The promising, albeit early, data from the study released Wednesday found that 100% of evaluable patients with either non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia who had relapsed following CAR-T treatments, and who had received an average of five lines of prior treatment, responded to Precision’s lead therapy PBCAR0191.